Filing identity and reporting period
Material metadata mismatch: The supplied filing is Heatwurx, Inc.’s Form 10-K for the fiscal year ended December 31, 2013, filed March 27, 2014. It is not a filing for Processa Pharmaceuticals, Inc. The filing does not report a 2013 fourth-quarter standalone 10-K; it includes unaudited quarterly results within the annual report.
Heatwurx was a development-stage asphalt repair equipment company. It described a hot-in-place recycling process and equipment for repairing pavement, and said it had not yet commercialized its products. Management anticipated commercialization during 2014.
Financial results and position
| Metric | FY 2013 | FY 2012 |
|---|---|---|
| Revenue | $312,480 | $192,145 |
| Gross profit | $124,478 | $58,890 |
| Gross margin | 39.8% | 30.6% |
| Operating expenses | $3,085,798 | $2,331,663 |
| Operating loss | $(2,961,320) | $(2,272,773) |
| Net loss | $(3,068,701) | $(2,440,538) |
| Cash used in operating activities | $(2,538,769) | $(1,892,500) |
| Cash and cash equivalents at year-end | $186,864 | $1,021,475 |
At December 31, 2013, total assets were $2.94 million, current assets $514,706, current liabilities $1.12 million, total liabilities $1.27 million, and stockholders’ equity $1.67 million. The current ratio was approximately 0.46. Disclosed debt included a $500,000 current senior subordinated note, $90,000 in unsecured notes, and $186,644 in equipment loans, of which $41,186 was current. Accumulated deficit was $6.81 million. No dividend was paid or expected in the foreseeable future.
Unaudited fourth-quarter 2013 revenue was $70,090 and net loss was $806,925. The filing’s quarterly EPS presentation is unclear in the supplied text.
Changes versus prior period
- Revenue rose approximately 63% year over year, while gross profit more than doubled; gross margin increased by about 9 percentage points.
- Net loss widened by approximately $628,000. SG&A increased by about $935,000, principally due to higher employee costs, depreciation and amortization, and business-development advertising and promotion.
- Research and development expense declined by approximately $181,000, mainly because of lower patent-related legal and consulting costs.
- Operating cash use increased by approximately $646,000, and year-end cash fell by approximately $835,000.
Outlook, risks and unusual items
- Going concern and funding: The auditor’s report and management state that recurring losses, minimal revenue, and limited cash raise substantial doubt about the company’s ability to continue as a going concern. Management estimated spending at about $300,000 per month and said at least $3.6 million would be needed to meet cash needs for the next 12 months. Continued operations depended on raising additional capital, principally from a small group of investors.
- Subsequent financing: After year-end, the company reported $850,000 in notes under a January 2014 debt financing, $159,996 from a Series D offering, and $150,000 received by March 27 under a new offering of up to $3 million in notes. The new debt carried 12% annual interest and warrants; proceeds were intended for debt repayment and working capital. The filing does not establish that the full required funding had been secured.
- Commercialization and execution: Sales remained limited, and the business depended on market acceptance, developing distribution and demonstration capacity, and completing product standardization. The company relied on a single manufacturer without a formal manufacturing agreement. In 2013, two customers accounted for 92% of revenue and two suppliers accounted for 95% of equipment purchases.
- Debt and related parties: A $250,000 payment on the $500,000 year-end senior subordinated note was made in February 2014, leaving $250,000 outstanding as of March 27. The note was payable to founder and consultant Richard Giles, who also received consulting fees. The filing disclosed other related-party financing and transactions.
- Acquisition and revenue recognition: In January 2014, Heatwurx acquired Dr. Pave, LLC, an entity controlled by its CEO, for 58,333 common shares valued at $175,000. A 2013 transaction involving approximately $155,000 of equipment and consumables was not recognized as revenue; it was treated as consigned inventory, with the related cash recorded as an advance-payment liability. The company subsequently assumed Dr. Pave’s short-term loan obligation.
- Other risks and contingencies: Risks included potential impairment of developed technology, warranty exposure, steel and component costs, competition, regulatory compliance, patent challenges, litigation and insurance adequacy, dilution from options and warrants, and reliance on key personnel. No material legal proceedings were reported. Two utility patents were issued in October 2013; a design patent issued in March 2014, and a third utility patent had received a notice of allowance.
Important facts for investors to verify
- Confirm that Heatwurx, Inc.—not Processa Pharmaceuticals, Inc.—is the intended issuer and that the intended period is fiscal 2013 rather than Q4 2013.
- Verify current cash, monthly cash burn, debt maturities, and whether subsequent financing was completed and sufficient to fund operations.
- Assess the basis for the going-concern conclusion and whether new funding changes that assessment.
- Review Dr. Pave’s acquisition accounting, related-party terms, assumed loan, and the treatment of the 2013 consigned sale.
- Track product commercialization, customer concentration, manufacturing alternatives, and the company’s ability to convert demonstrations into recurring sales.
- Check potential dilution from preferred shares, warrants and stock options, and the status of patent applications and technology impairment testing.